Toreforant

N/A

Report date: 2022/06/27 20:00:35
NME

Base Information

Drug NameToreforant
Drug Alias Name托瑞福兰ToreforantumH4R antagonist托瑞仑特Histamine 4 Receptor antagonist +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H4 receptor antagonists
TargetsHistamine H4 receptor
Therapy Area/IndicationsPsoriasisAsthmaHepatic Insufficiency +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesXian Janssen Pharmaceutical LtdJohnson & Johnson LtdJanssen Research & Development Llc +[4] 
Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsAsthma
Inactive IndicationsPsoriasisHepatic InsufficiencyArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksKEGG